Proposal to Examine the Effect of Fecal Transplantation on Obesity
关键词
抽象
描述
We propose to transplant feces from thin, disease-free donors into obese patients undergoing colonoscopy for screening for colorectal carcinoma.
We will obtain feces from healthy donors with a BMI of between 21-24, in accordance with the Protocol that was approved by the Israel Ministry of Health. The stool sample will be prepared as detailed below :
We will perform colonoscopy on healthy patients with a BMI of 30-40 kg/m2 who have a clear indication for a screening examination. These will be people who are above the age of 50 who have not had a screening colonoscopy in the last 10 years, or those with a family history of carcinoma of the colon who are over the age of 40 years.
All patients will undergo a screening colonoscopy and will be allocated to receive either 250 ml of diluted fecal material prepared from a screened donor, or an equivalent volume of normal saline (sham transplantation). The material will be injected in the amount of 50 ml at five locations- the terminal ileum (or the cecum if the terminal ileum cannot be intubated), ascending colon, transverse colon, descending colon and sigmoid colon- during withdrawal of the colonoscope from the cecum. The stool will not be delivered to the endoscopy suite until the patient is sedated and only the endoscopist performing the procedure will know what treatment arm the patient is in.
In addition, all patients participating in the study will receive standard advice regarding weight loss and physical activity (at least 90 minutes of walking for week) from a staff dietitian.
Stool samples will be obtained from the donor( from the stool donated for transplantation) and the patients at baseline (prior to transplantation), 1 month and 12 months and frozen at -80 C for high throughput analysis by standard techniques.
The patients will be reviewed at 1 3 6 and 12 months. At this time note will be made of their weight, BMI and waist circumference. In addition note will be made of their fasting glucose and lipid profile.
日期
| 最后验证: | 11/30/2014 |
| 首次提交: | 01/07/2015 |
| 提交的预估入学人数: | 01/11/2015 |
| 首次发布: | 01/12/2015 |
| 上次提交的更新: | 01/11/2015 |
| 最近更新发布: | 01/12/2015 |
| 实际学习开始日期: | 11/30/2014 |
| 预计主要完成日期: | 11/30/2015 |
| 预计完成日期: | 11/30/2016 |
状况或疾病
干预/治疗
Other: intervention
Other: placebo
相
手臂组
| 臂 | 干预/治疗 |
|---|---|
| Placebo Comparator: placebo 250 ml of normal saline (sham transplantation). | Other: placebo All patients will undergo a screening colonoscopy and will be allocated to receive either 250 ml of diluted fecal material prepared from a screened donor, or an equivalent volume of normal saline (sham transplantation). |
| Active Comparator: intervention 250 ml of diluted fecal material prepared from a screened donor | Other: intervention . All patients will undergo a screening colonoscopy and will be allocated to receive either 250 ml of diluted fecal material prepared from a screened donor, or an equivalent volume of normal saline (sham transplantation). |
资格标准
| 有资格学习的年龄 | 40 Years 至 40 Years |
| 有资格学习的性别 | All |
| 接受健康志愿者 | 是 |
| 标准 | Inclusion Criteria: - healthy patients with a BMI of 30-40 kg/m2 who have a clear indication for a screening examination. These will be people who are above the age of 50 who have not had a screening colonoscopy in the last 10 years, or those with a family history of carcinoma of the colon who are over the age of 40 years. Exclusion Criteria: - Exclusion criteria include hepatitis B and C infection, - consumption of more than 20 gram of alcohol per day, - diabetes mellitus treated with insulin, - previous unstable coronary artery disease in the last year, - HIV infection, - concomitant use of corticosteroids in the previous 3 months and severe diverticulosis. If patients were to receive antibiotic therapy during the year of follow up of the study, data will only be included in the analysis prior to this time. |
结果
主要结果指标
1. weight loss [one year]
